Johnson & Johnson Q3 26 Earnings:

- Adj EPS: $2.59 (est $2.52)
- Sales: $25.40B (est $25.4B)
- Medicine Rev: $16.76B (est $16.59B)
- Darzalex Rev: $4.24B (est $4.31B)
- Tremfya Rev: $2.40B (est $2.21B)
- MedTech Sales: $8.64B (est $8.77B)
- Sees FY Sales: $101B To $101.4B (est $100.8B To $101.4B)
- Sees FY Adj EPS: $11.05 To $11.15 (est $10.96 To $11.11)
- Sees FY Adj Oper EPS: $10.95 To $11.05 (est $10.86 To $11.01)
- CFO Says Leaning Toward Orthopaedic Unit Spinoff Instead Of Sale
(@FirstSquaw)